Description
Triclabenchrist (Triclabendazole) 500 mg
Triclabenchrist is a brand name for triclabendazole, an antiparasitic medicine used for infections caused by liver flukes, especially fascioliasis. Human regulatory information and clinical literature identify triclabendazole as the key active ingredient, with established use against Fasciola species.
Active Ingredient and Medicine Class
Triclabendazole is a benzimidazole anthelmintic. Medicines in this class are used against parasitic worms. Triclabendazole is distinguished by activity against both immature and adult liver flukes.
Established Medical Uses
The established human use of triclabendazole is treatment of fascioliasis, a parasitic infection caused by liver flukes. Published reviews and clinical studies support its role as the main drug used for this infection, including in adults and children.
How It Works
Triclabendazole acts on the parasite’s structures and metabolism, leading to loss of function and death of the fluke. It has particular activity against early and mature stages of Fasciola, which is why it is considered important for liver fluke infection. The exact resistance mechanisms in parasites are complex and have been studied in the scientific literature.
Important Safety Information
Triclabendazole should not be used in people with known hypersensitivity to triclabendazole or related ingredients. Liver involvement is part of fascioliasis itself, and clinical sources note that abnormal liver tests and abdominal symptoms can be present before treatment or appear around the time parasites are cleared. Clinically significant interactions have not been as extensively characterised as for many other medicines, so product-specific prescribing information should always be checked.
Possible Side Effects
Reported adverse effects include abdominal pain, nausea, vomiting, diarrhoea, headache, and urticaria or other skin reactions. Some patients may also show eosinophilia or temporary changes in liver laboratory tests after treatment. Serious reactions are uncommon but should be considered, especially if symptoms of allergy or marked liver problems occur.
Scientific Evidence
Clinical trials and reviews published in PubMed describe triclabendazole as highly effective for human fascioliasis, including chronic infection. The evidence base includes randomized and community-based studies, as well as later review articles summarising broad clinical experience and supporting its role as the main treatment option for this infection.
Medical Information Notice
This educational summary is based on sources available at the time of review and does not replace the official patient leaflet, product information, or assessment by a qualified healthcare professional.
Medical Sources
- FDA — Triclabendazole
- Gandhi P, et al. — Triclabendazole in the treatment of human fascioliasis: a review — Transactions of the Royal Society of Tropical Medicine and Hygiene (2019)